Enzymit

Enzymit

Private
IsraelHealthcare & Life Scienceshttps://www.enzymit.com

Last Round

Series A

Sep 25, 2024

Total Funding Raised

$15M

Momentum Score

25 /100

Company Overview

Enzymit is a biotechnology company that specializes in developing innovative enzymes through a discovery platform that leverages deep learning algorithms and high-throughput testing for diverse applications, including fine chemical manufacturing, food technology, health, and biodefense, helping global manufacturers enhance production efficiency, lower costs, and support sustainability.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, ML Platforms, Clean Manufacturing, Pharma Supply Chain, Sustainable Materials

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Infrastructure

Keywords

synthetic biologycell-free bioproductionsynbioenzyme designcustom enzymesbiomanufacturingcomputational enzyme designenzyme engineeringfermentation alternativeAI for biologyprotein engineeringB2B ingredient supplyHyaluronic AcidHAHuman Milk OligosaccharidesHMOsspecialty chemicals

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Enzymit Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Enzymit Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series ASep 25, 2024
SeedApr 6, 2022

Key People

Founding team and executive leadership

Dror Baran

Chief Operating Officer And Co-Founder

Founding Team

Gideon Lapidoth

Chief Executive Officer And Co-founder Of Enzymit

Founding Team

Enzymit Investors

Notable investors and investment history

InvestorRounds
Khosla VenturesSeries A
Grove VenturesSeries A
First Star VenturesSeries A, Seed
Sapir Venture PartnersSeries A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 10, 2025

    First company to produce Hyaluronic Acid via enzymatic, cell-free process.

  • Oct 17, 2025

    Partnered with Cosun for cell-free Hyaluronic Acid production.

Enzymit Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Enzymit Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Enzymit's valuation, stock price, and market status.

Firmographic Details

HeadquartersIsrael
Employee Range26
Year Founded2020
Last FundingSep 25, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.